This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsCARGO Therapeutics（CRGX）株式概要CARGO Therapeutics, Inc.は臨床段階のバイオテクノロジー企業で、米国においてがん患者を治癒させる可能性のある細胞療法の設計、エンジニアリング、開発に注力している。 詳細CRGX ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長2/6過去の実績0/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より98.8%で取引されている 収益は年間66.83%増加すると予測されています リスク分析収益が 100 万ドル未満 ( $0 )現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るCRGX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$4.47該当なし内在価値ディスカウントEst. Revenue$PastFuture-222m132016201920222025202620282031Revenue US$12.9Earnings US$2.3AdvancedSet Fair ValueView all narrativesCARGO Therapeutics, Inc. 競合他社Tiziana Life SciencesSymbol: NasdaqCM:TLSAMarket cap: US$188.9mMonopar TherapeuticsSymbol: NasdaqCM:MNPRMarket cap: US$422.8mProQR TherapeuticsSymbol: NasdaqCM:PRQRMarket cap: US$164.4mAlectorSymbol: NasdaqGS:ALECMarket cap: US$245.4m価格と性能株価の高値、安値、推移の概要CARGO Therapeutics過去の株価現在の株価US$4.4752週高値US$25.4552週安値US$3.00ベータ01ヶ月の変化-1.11%3ヶ月変化9.02%1年変化-74.31%3年間の変化n/a5年間の変化n/aIPOからの変化-69.24%最新ニュースお知らせ • Aug 21+ 1 more updateCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from S&P Global BMI IndexCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from S&P Global BMI Indexお知らせ • Aug 20+ 1 more updateCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from NASDAQ Composite IndexCARGO Therapeutics, Inc. has been dropped from the Nasdaq Composite Index.お知らせ • Aug 19+ 21 more updatesCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from NASDAQ Biotechnology IndexCARGO Therapeutics, has been dropped from the NASDAQ Biotechnology Index.Price Target Changed • Jul 23Price target decreased by 52% to US$5.33Down from US$11.18, the current price target is an average from 3 analysts. New target price is 19% above last closing price of US$4.48. The company is forecast to post a net loss per share of US$2.69 next year compared to a net loss per share of US$3.72 last year.お知らせ • Jul 08Concentra Biosciences, LLC agreed to acquire CARGO Therapeutics, Inc. (NasdaqGS:CRGX) in a tender offer transaction.Concentra Biosciences, LLC agreed to acquire CARGO Therapeutics, Inc. (NasdaqGS:CRGX) in a tender offer transaction on July 7, 2025. A cash consideration of $0.15 million valued at $0.679 per share and of $200.8 million valued at $4.379 per share will be paid by Concentra Biosciences, LLC. As part of consideration, $4.04 million is paid towards Company Restricted Stock, $1.14 million is paid towards Restricted Stock Units, $199.66 million is paid towards common equity and $0.15 million is paid towards options of CARGO Therapeutics, Inc. as part of the consideration additionally one non-transferable contingent value right, which represents the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO’s product candidates that occurs within two years following closing, each pursuant to a contingent value rights agreement. In case of termination of transaction, Concentra Biosciences, LLC will pay a termination fee of $0.50 million and CARGO Therapeutics, Inc. will pay a termination fee of $3.80 million. The transaction is subject to minimum tender. The expected completion of the transaction is August 2025 TD Securities LLC acted as financial advisor for CARGO Therapeutics, Inc. Latham & Watkins LLP acted as legal advisor for CARGO Therapeutics, Inc. Gibson, Dunn & Crutcher LLP acted as legal advisor for Concentra Biosciences, LLC. TD Securities LLC acted as fairness opinion provider for CARGO Therapeutics, Inc.お知らせ • Jun 30+ 5 more updatesCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from Russell 3000E Growth IndexCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from Russell 3000E Growth Index最新情報をもっと見るRecent updatesお知らせ • Aug 21+ 1 more updateCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from S&P Global BMI IndexCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from S&P Global BMI Indexお知らせ • Aug 20+ 1 more updateCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from NASDAQ Composite IndexCARGO Therapeutics, Inc. has been dropped from the Nasdaq Composite Index.お知らせ • Aug 19+ 21 more updatesCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from NASDAQ Biotechnology IndexCARGO Therapeutics, has been dropped from the NASDAQ Biotechnology Index.Price Target Changed • Jul 23Price target decreased by 52% to US$5.33Down from US$11.18, the current price target is an average from 3 analysts. New target price is 19% above last closing price of US$4.48. The company is forecast to post a net loss per share of US$2.69 next year compared to a net loss per share of US$3.72 last year.お知らせ • Jul 08Concentra Biosciences, LLC agreed to acquire CARGO Therapeutics, Inc. (NasdaqGS:CRGX) in a tender offer transaction.Concentra Biosciences, LLC agreed to acquire CARGO Therapeutics, Inc. (NasdaqGS:CRGX) in a tender offer transaction on July 7, 2025. A cash consideration of $0.15 million valued at $0.679 per share and of $200.8 million valued at $4.379 per share will be paid by Concentra Biosciences, LLC. As part of consideration, $4.04 million is paid towards Company Restricted Stock, $1.14 million is paid towards Restricted Stock Units, $199.66 million is paid towards common equity and $0.15 million is paid towards options of CARGO Therapeutics, Inc. as part of the consideration additionally one non-transferable contingent value right, which represents the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO’s product candidates that occurs within two years following closing, each pursuant to a contingent value rights agreement. In case of termination of transaction, Concentra Biosciences, LLC will pay a termination fee of $0.50 million and CARGO Therapeutics, Inc. will pay a termination fee of $3.80 million. The transaction is subject to minimum tender. The expected completion of the transaction is August 2025 TD Securities LLC acted as financial advisor for CARGO Therapeutics, Inc. Latham & Watkins LLP acted as legal advisor for CARGO Therapeutics, Inc. Gibson, Dunn & Crutcher LLP acted as legal advisor for Concentra Biosciences, LLC. TD Securities LLC acted as fairness opinion provider for CARGO Therapeutics, Inc.お知らせ • Jun 30+ 5 more updatesCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from Russell 3000E Growth IndexCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from Russell 3000E Growth IndexRecent Insider Transactions • May 18Interim CEO recently sold US$105k worth of stockOn the 14th of May, Anup Radhakrishnan sold around 27k shares on-market at roughly US$3.84 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Anup has been a net seller over the last 12 months, reducing personal holdings by US$112k.お知らせ • May 01CARGO Therapeutics, Inc., Annual General Meeting, Jun 18, 2025CARGO Therapeutics, Inc., Annual General Meeting, Jun 18, 2025.分析記事 • Mar 26Here's Why We're Watching CARGO Therapeutics' (NASDAQ:CRGX) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...New Risk • Mar 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$129m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding).Price Target Changed • Mar 19Price target decreased by 28% to US$9.74Down from US$13.50, the current price target is an average from 5 analysts. New target price is 135% above last closing price of US$4.15. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$2.67 next year compared to a net loss per share of US$3.72 last year.お知らせ • Mar 19+ 1 more updateCARGO Therapeutics, Inc. Announces CEO ChangesCARGO Therapeutics, Inc. announced on March 13, 2025, in connection with the determination of the board to suspend all ongoing pipeline development efforts and continue to explore potential strategic alternatives, Gina Chapman, the company’s CEO will be leaving the company effective May 19, 2025. On March 13, 2025, the board appointed Anup Radhakrishnan, the company’s chief financial officer and chief operating officer, to succeed Ms. Chapman as interim CEO. Mr. Radhakrishnan, age 45, has served as the Company’s Chief Financial Officer since August 2022 and as its Chief Operating Officer since October 2024.Price Target Changed • Mar 17Price target increased by 15% to US$15.54Up from US$13.50, the current price target is an average from 6 analysts. New target price is 278% above last closing price of US$4.11. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$2.12 next year compared to a net loss per share of US$3.72 last year.Seeking Alpha • Mar 03CARGO Therapeutics: A Gutted CAR T Player Trying To Find New DirectionSummary CARGO Therapeutics was a phase 2 company that announced termination of their main program. New clinical projects are not set to enter phase 1 study until later 2025. Cash runway is robust for now, taking CRGX into 2028 after a planned workforce reduction. The company has an interesting new approach for B-cell malignancies, but their ability to find a clear direction is very much up in the air. Read the full article on Seeking AlphaNew Risk • Jan 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$130m net loss in 3 years).Price Target Changed • Jan 30Price target decreased by 52% to US$15.40Down from US$32.00, the current price target is an average from 5 analysts. New target price is 354% above last closing price of US$3.39. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$3.69 next year compared to a net loss per share of US$16.53 last year.お知らせ • Jan 30CARGO Therapeutics, Inc. to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic OptionsCARGO Therapeutics, Inc. announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. In-line with this decision, the Company will reduce its workforce to extend cash runway and prioritize the advancement of CRG-023 to Phase 1 proof-of-concept data as well as its novel allogeneic platform. Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the intended patient population. While data from 51 patients with at least one post baseline scan demonstrated an overall response rate of 77% and complete response rate of 43%, the durability of CR at three months was 18%. Safety data indicated 18% of patients developed immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) that were grade 3 or higher, including grade 4 and grade 5 serious adverse events. IEC-HS is a toxicity that is associated with CAR T-cell therapy and firi-cel in other clinical studies. The Company is implementing a workforce reduction of approximately 50% to preserve cash. Further, CARGO will continue to advance CRG-023, its tri-specific CAR T, into a Phase 1 dose escalation study and its allogeneic platform to lead vector candidate selection while evaluating its strategic options. With preliminary cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024, the Company expects its cash runway to be extended into mid-2028. CARGO intends to present an analysis of the FIRCE-1 Phase 2 study at a future medical conference.分析記事 • Nov 28Here's Why We're Not Too Worried About CARGO Therapeutics' (NASDAQ:CRGX) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...New Risk • Nov 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 5.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 5.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$231m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding).お知らせ • Nov 05CARGO Therapeutics, Inc. Announces ASH 2024 Abstract on CRG-023, a Tri-Specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma ActivityCARGO Therapeutics, Inc. announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66thAmerican Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego, California. Additionally, the data showed that CRG-023 T cells were able to durably clear tumor cells in models mimicking antigen loss in contrast to mono-CAR T cells such as FMC63-containing CD19 CAR T cells. Details of CARGO's presentation are as follows: Title: CRG-023 Is a Novel Tri-Specific CAR T Product candidate Engineered to Prevent Antigen Escape and Sustain durable Anti-Tumor Functionality Against B-Cell Malignancies. The abstract reviews the CRG-023 construct design, including the discovery of novel CD19 and CD20 scFv binders, selected for enhanced CAR performance, that were combined with the existing CD22 scFv binder used in firicabtagene autoleucel (firi-cel). The iterative engineering of the construct allowed for the selection of the optimal costimulatory domain configuration and optimal assemblage in a unique tri-cistronic lentiviral vector designed to maximize durable anti-tumor response. Importantly, in these mouse models, CRG-023 CAR T cells were able to sustain durable in vitro anti-tumor activity despite repeated tumor challenge against tumor cells expressing all or any one of the three antigens. Superior tumor control was observed as compared to benchmark CAR T cells, without increased cytokine secretion and while sustaining a less effector-differentiated phenotype. In vivo studies showed that CRG-023 CAR T cells were highly active and able to clear Raji lymphoma tumor cells expressing the three target antigens in a dose-response manner and down to the lowest dose tested (1x10CAR cells). Additionally, the data showed that CRG-023 T cells were able to durably clear tumor cells in models mimicking antigen loss in contrast to mono-CAR T cells such as FMC63-containing CD19 CAR T cells.New Risk • Sep 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$201m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).Recent Insider Transactions Derivative • Sep 20President notifies of intention to sell stockGina Chapman intends to sell 75k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of September. If the sale is conducted around the recent share price of US$23.33, it would amount to US$1.7m. For the year to December 2022, Gina's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2023, Gina has owned 103.91k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.New Risk • Jul 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.6% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$200m net loss in 3 years).Buy Or Sell Opportunity • Jun 17Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 42% to US$15.92. The fair value is estimated to be US$20.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only.お知らせ • Jun 06CARGO Therapeutics, Inc. Announces the Appointment of Jane Pritchett Henderson as Independent DirectorCARGO Therapeutics, Inc. announced the appointment of Jane Pritchett Henderson to its Board of Directors. Ms. Henderson will also serve as a member of the audit and compensation committees. Ms. Henderson has served as Chief Financial Officer of Apogee Therapeutics since January 2023. Prior to joining Apogee, she served as the Chief Financial Officer and Chief Business Officer of Adagio Therapeutics (now Invivyd, Inc.). She has also served as Chief Financial Officer of Turnstone Biologics, Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, and as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals. Prior to Kolltan Pharmaceuticals, Ms. Henderson served in various financial and business development executive roles at biopharmaceutical companies after spending almost 20 years in healthcare investment banking. She currently serves on the Board of Directors of Akero Therapeutics, Inc. and Ventus Therapeutics and had previously served on the Board of IVERIC (formerly Ophthotech) and Sesen Bio (formerly Eleven Bio).お知らせ • May 29CARGO Therapeutics, Inc. announced that it expects to receive $110.007 million in fundingCARGO Therapeutics, Inc. announced it has entered into a Securities Purchase Agreement of 6,471,000 shares of the Company’s common stock $0.001 par value per share at issue price $17 for gross proceeds $110,007,000 on May 28, 2024. The closing of the Private Placement is expected to occur on May 30, 2024, subject to the satisfaction of customary closing conditions.分析記事 • May 10CARGO Therapeutics (NASDAQ:CRGX) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Buy Or Sell Opportunity • May 03Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to US$20.33. The fair value is estimated to be US$25.61, however this is not to be taken as a buy recommendation but rather should be used as a guide only.お知らせ • Apr 27CARGO Therapeutics, Inc., Annual General Meeting, Jun 04, 2024CARGO Therapeutics, Inc., Annual General Meeting, Jun 04, 2024, at 09:00 Pacific Standard Time. Agenda: To elect two Class I directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected; to consider and ratify the appointment, by the Audit Committee of the company's Board of Directors, of Deloitte & Touche LLP as the independent registered public accounting firm and independent auditor of the company for its year ending December 31, 2024; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.お知らせ • Apr 16CARGO Therapeutics, Inc. Appoints Kapil Dhingra to Board of DirectorsCARGO Therapeutics, Inc. announced it has appointed Kapil Dhingra, M.B.B.S., to the Company’s Board of Directors. Dr. Dhingra is a medical oncologist and a physician-scientist bringing more than 25 years of strategic clinical development experience in oncology, including cell therapy, with a proven track record in drug development, patient care and academic research. Dr. Dhingra’s development experience spans several oncology companies, both as a Board member or in senior leadership. He is currently Chairman of the Board for LAVA Therapeutics, a member of the Board of Supervisors for Servier and a member of the Board of Directors of Black Diamond Therapeutics, Inc., Replimune, Inc., and Median Technologies. He previously served on the Board of Autolus Therapeutics plc from the company’s inception until the recent Biologics License Application (BLA) filing of its CAR T-cell therapy.In 2008, Dr. Dhingra founded and continues to be a managing member of KAPital Consulting, LLC, a healthcare consulting firm providing strategic advisory services to biotechnology companies. Previously he served as Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at The Roche Group (Roche), during which he led numerous drug approvals. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Dr. Dhingra has also served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine and Memorial Sloan Kettering Cancer Center.Buy Or Sell Opportunity • Apr 02Now 20% undervaluedOver the last 90 days, the stock has risen 4.1% to US$20.91. The fair value is estimated to be US$26.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only.Seeking Alpha • Jan 28Cargo Therapeutics: High Venture Interest But Still Early Days For This CAR-T PlayerSummary CARGO Therapeutics is developing cell therapies for cancer patients, with a focus on CD22 targeting CAR-T therapy. The company plans to initiate a Phase 2 program in LBCL - CAR T naïve based on data from ongoing clinical trials. The FDA has issued a safety labeling change for all CAR-T therapies, requiring a warning label due to the risk of T cell malignancies. CRG-022 needs to be differentiated from existing CAR-Ts. Read the full article on Seeking AlphaBoard Change • Dec 31High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. Director Abe Bassan is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Dec 07CARGO Therapeutics, Inc. Announces Formation Scientific Advisory BoardCARGO Therapeutics, Inc. announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy. The SAB will be chaired by Robbie Majzner, MD, co-founder of CARGO and Director of the Pediatric and Young Adult Cancer Cell Therapy Program within the Departments of Pediatric Oncology and Medical Oncology at Dana Farber Cancer Institute and the Division of Hematology/Oncology at Boston Children’s Hospital. Members of the CARGO Scientific Advisory Board are listed below. Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair, and Director of the Pediatric and Young Adult Cancer Cell Therapy Program within the Departments of Pediatric Oncology and Medical Oncology at Dana Farber Cancer Institute and the Division of Hematology/Oncology at Boston Children’s Hospital. Stephen Gottschalk, MD, Chair of the Department of Bone Marrow Transplantation and Cellular Therapy at St Jude Children’s Research Hospital. Andras Attila Heczey, MD, Professor, Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology and Oncology. Marcela Maus, MD, PhD, Associate Professor at Harvard Medical School, the Paula O’Keefe Chair in Oncology, Director of Cellular Immunotherapy at Massachusetts General Hospital (MGH) Cancer Center, Attending Physician in the Hematopoietic Cell Transplant and Cell Therapy Division of Oncology at MGH. Cameron Turtle, MBBS, PhD, Professor and CLEARbridge Chair in Cancer Immunotherapy in the Faculty of Medicine and Health at the University of Sydney; Clinical academic physician at Royal North Shore Hospital, Sydney, Australia.お知らせ • Nov 11CARGO Therapeutics, Inc. has completed an IPO in the amount of $281.25 million.CARGO Therapeutics, Inc. has completed an IPO in the amount of $281.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,750,000 Price\Range: $15 Transaction Features: Sponsor Backed Offering株主還元CRGXUS BiotechsUS 市場7D0.2%1.2%1.1%1Y-74.3%34.6%28.7%株主還元を見る業界別リターン: CRGX過去 1 年間で34.6 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: CRGXは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is CRGX's price volatile compared to industry and market?CRGX volatilityCRGX Average Weekly Movement3.6%Biotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: CRGX 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: CRGXの 週次ボラティリティ は、過去 1 年間で14%から4%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2019167Anup Radhakrishnancargo-tx.comCARGO Therapeutics, Inc.は臨床段階のバイオテクノロジー企業で、米国においてがん患者を治癒する可能性のある細胞療法の設計、エンジニアリング、開発に注力している。同社は、3つのB細胞悪性腫瘍細胞を標的とする第1相段階にある3特異的CAR T製品候補であるCRG-023と、CAR T細胞療法の持続的な反応を可能にするために免疫ベースの拒絶反応を効果的に制限するように設計されたユニバーサルベクターソリューションである同種移植プラットフォームを開発している。同社は以前Syncopation Life Sciences, Inc.として知られていたが、2022年9月にCARGO Therapeutics, Inc.に社名を変更した。CARGO Therapeutics, Inc.は2019年に法人化され、カリフォルニア州サンカルロスを拠点としている。もっと見るCARGO Therapeutics, Inc. 基礎のまとめCARGO Therapeutics の収益と売上を時価総額と比較するとどうか。CRGX 基礎統計学時価総額US$216.19m収益（TTM）-US$221.78m売上高(TTM)n/a0.0xP/Sレシオ-1.0xPER（株価収益率CRGX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CRGX 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$221.78m収益-US$221.78m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）-4.59グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%CRGX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/20 15:53終値2025/08/18 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CARGO Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Yevgeniya LivshitsChardan Capital Markets, LLCRobert BurnsH.C. Wainwright & Co.Michael YeeJefferies LLC2 その他のアナリストを表示
お知らせ • Aug 21+ 1 more updateCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from S&P Global BMI IndexCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from S&P Global BMI Index
お知らせ • Aug 20+ 1 more updateCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from NASDAQ Composite IndexCARGO Therapeutics, Inc. has been dropped from the Nasdaq Composite Index.
お知らせ • Aug 19+ 21 more updatesCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from NASDAQ Biotechnology IndexCARGO Therapeutics, has been dropped from the NASDAQ Biotechnology Index.
Price Target Changed • Jul 23Price target decreased by 52% to US$5.33Down from US$11.18, the current price target is an average from 3 analysts. New target price is 19% above last closing price of US$4.48. The company is forecast to post a net loss per share of US$2.69 next year compared to a net loss per share of US$3.72 last year.
お知らせ • Jul 08Concentra Biosciences, LLC agreed to acquire CARGO Therapeutics, Inc. (NasdaqGS:CRGX) in a tender offer transaction.Concentra Biosciences, LLC agreed to acquire CARGO Therapeutics, Inc. (NasdaqGS:CRGX) in a tender offer transaction on July 7, 2025. A cash consideration of $0.15 million valued at $0.679 per share and of $200.8 million valued at $4.379 per share will be paid by Concentra Biosciences, LLC. As part of consideration, $4.04 million is paid towards Company Restricted Stock, $1.14 million is paid towards Restricted Stock Units, $199.66 million is paid towards common equity and $0.15 million is paid towards options of CARGO Therapeutics, Inc. as part of the consideration additionally one non-transferable contingent value right, which represents the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO’s product candidates that occurs within two years following closing, each pursuant to a contingent value rights agreement. In case of termination of transaction, Concentra Biosciences, LLC will pay a termination fee of $0.50 million and CARGO Therapeutics, Inc. will pay a termination fee of $3.80 million. The transaction is subject to minimum tender. The expected completion of the transaction is August 2025 TD Securities LLC acted as financial advisor for CARGO Therapeutics, Inc. Latham & Watkins LLP acted as legal advisor for CARGO Therapeutics, Inc. Gibson, Dunn & Crutcher LLP acted as legal advisor for Concentra Biosciences, LLC. TD Securities LLC acted as fairness opinion provider for CARGO Therapeutics, Inc.
お知らせ • Jun 30+ 5 more updatesCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from Russell 3000E Growth IndexCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from Russell 3000E Growth Index
お知らせ • Aug 21+ 1 more updateCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from S&P Global BMI IndexCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from S&P Global BMI Index
お知らせ • Aug 20+ 1 more updateCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from NASDAQ Composite IndexCARGO Therapeutics, Inc. has been dropped from the Nasdaq Composite Index.
お知らせ • Aug 19+ 21 more updatesCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from NASDAQ Biotechnology IndexCARGO Therapeutics, has been dropped from the NASDAQ Biotechnology Index.
Price Target Changed • Jul 23Price target decreased by 52% to US$5.33Down from US$11.18, the current price target is an average from 3 analysts. New target price is 19% above last closing price of US$4.48. The company is forecast to post a net loss per share of US$2.69 next year compared to a net loss per share of US$3.72 last year.
お知らせ • Jul 08Concentra Biosciences, LLC agreed to acquire CARGO Therapeutics, Inc. (NasdaqGS:CRGX) in a tender offer transaction.Concentra Biosciences, LLC agreed to acquire CARGO Therapeutics, Inc. (NasdaqGS:CRGX) in a tender offer transaction on July 7, 2025. A cash consideration of $0.15 million valued at $0.679 per share and of $200.8 million valued at $4.379 per share will be paid by Concentra Biosciences, LLC. As part of consideration, $4.04 million is paid towards Company Restricted Stock, $1.14 million is paid towards Restricted Stock Units, $199.66 million is paid towards common equity and $0.15 million is paid towards options of CARGO Therapeutics, Inc. as part of the consideration additionally one non-transferable contingent value right, which represents the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO’s product candidates that occurs within two years following closing, each pursuant to a contingent value rights agreement. In case of termination of transaction, Concentra Biosciences, LLC will pay a termination fee of $0.50 million and CARGO Therapeutics, Inc. will pay a termination fee of $3.80 million. The transaction is subject to minimum tender. The expected completion of the transaction is August 2025 TD Securities LLC acted as financial advisor for CARGO Therapeutics, Inc. Latham & Watkins LLP acted as legal advisor for CARGO Therapeutics, Inc. Gibson, Dunn & Crutcher LLP acted as legal advisor for Concentra Biosciences, LLC. TD Securities LLC acted as fairness opinion provider for CARGO Therapeutics, Inc.
お知らせ • Jun 30+ 5 more updatesCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from Russell 3000E Growth IndexCARGO Therapeutics, Inc.(NasdaqGS:CRGX) dropped from Russell 3000E Growth Index
Recent Insider Transactions • May 18Interim CEO recently sold US$105k worth of stockOn the 14th of May, Anup Radhakrishnan sold around 27k shares on-market at roughly US$3.84 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Anup has been a net seller over the last 12 months, reducing personal holdings by US$112k.
お知らせ • May 01CARGO Therapeutics, Inc., Annual General Meeting, Jun 18, 2025CARGO Therapeutics, Inc., Annual General Meeting, Jun 18, 2025.
分析記事 • Mar 26Here's Why We're Watching CARGO Therapeutics' (NASDAQ:CRGX) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
New Risk • Mar 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$129m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding).
Price Target Changed • Mar 19Price target decreased by 28% to US$9.74Down from US$13.50, the current price target is an average from 5 analysts. New target price is 135% above last closing price of US$4.15. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$2.67 next year compared to a net loss per share of US$3.72 last year.
お知らせ • Mar 19+ 1 more updateCARGO Therapeutics, Inc. Announces CEO ChangesCARGO Therapeutics, Inc. announced on March 13, 2025, in connection with the determination of the board to suspend all ongoing pipeline development efforts and continue to explore potential strategic alternatives, Gina Chapman, the company’s CEO will be leaving the company effective May 19, 2025. On March 13, 2025, the board appointed Anup Radhakrishnan, the company’s chief financial officer and chief operating officer, to succeed Ms. Chapman as interim CEO. Mr. Radhakrishnan, age 45, has served as the Company’s Chief Financial Officer since August 2022 and as its Chief Operating Officer since October 2024.
Price Target Changed • Mar 17Price target increased by 15% to US$15.54Up from US$13.50, the current price target is an average from 6 analysts. New target price is 278% above last closing price of US$4.11. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$2.12 next year compared to a net loss per share of US$3.72 last year.
Seeking Alpha • Mar 03CARGO Therapeutics: A Gutted CAR T Player Trying To Find New DirectionSummary CARGO Therapeutics was a phase 2 company that announced termination of their main program. New clinical projects are not set to enter phase 1 study until later 2025. Cash runway is robust for now, taking CRGX into 2028 after a planned workforce reduction. The company has an interesting new approach for B-cell malignancies, but their ability to find a clear direction is very much up in the air. Read the full article on Seeking Alpha
New Risk • Jan 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$130m net loss in 3 years).
Price Target Changed • Jan 30Price target decreased by 52% to US$15.40Down from US$32.00, the current price target is an average from 5 analysts. New target price is 354% above last closing price of US$3.39. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$3.69 next year compared to a net loss per share of US$16.53 last year.
お知らせ • Jan 30CARGO Therapeutics, Inc. to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic OptionsCARGO Therapeutics, Inc. announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. In-line with this decision, the Company will reduce its workforce to extend cash runway and prioritize the advancement of CRG-023 to Phase 1 proof-of-concept data as well as its novel allogeneic platform. Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the intended patient population. While data from 51 patients with at least one post baseline scan demonstrated an overall response rate of 77% and complete response rate of 43%, the durability of CR at three months was 18%. Safety data indicated 18% of patients developed immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) that were grade 3 or higher, including grade 4 and grade 5 serious adverse events. IEC-HS is a toxicity that is associated with CAR T-cell therapy and firi-cel in other clinical studies. The Company is implementing a workforce reduction of approximately 50% to preserve cash. Further, CARGO will continue to advance CRG-023, its tri-specific CAR T, into a Phase 1 dose escalation study and its allogeneic platform to lead vector candidate selection while evaluating its strategic options. With preliminary cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024, the Company expects its cash runway to be extended into mid-2028. CARGO intends to present an analysis of the FIRCE-1 Phase 2 study at a future medical conference.
分析記事 • Nov 28Here's Why We're Not Too Worried About CARGO Therapeutics' (NASDAQ:CRGX) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
New Risk • Nov 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 5.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 5.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$231m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding).
お知らせ • Nov 05CARGO Therapeutics, Inc. Announces ASH 2024 Abstract on CRG-023, a Tri-Specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma ActivityCARGO Therapeutics, Inc. announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66thAmerican Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego, California. Additionally, the data showed that CRG-023 T cells were able to durably clear tumor cells in models mimicking antigen loss in contrast to mono-CAR T cells such as FMC63-containing CD19 CAR T cells. Details of CARGO's presentation are as follows: Title: CRG-023 Is a Novel Tri-Specific CAR T Product candidate Engineered to Prevent Antigen Escape and Sustain durable Anti-Tumor Functionality Against B-Cell Malignancies. The abstract reviews the CRG-023 construct design, including the discovery of novel CD19 and CD20 scFv binders, selected for enhanced CAR performance, that were combined with the existing CD22 scFv binder used in firicabtagene autoleucel (firi-cel). The iterative engineering of the construct allowed for the selection of the optimal costimulatory domain configuration and optimal assemblage in a unique tri-cistronic lentiviral vector designed to maximize durable anti-tumor response. Importantly, in these mouse models, CRG-023 CAR T cells were able to sustain durable in vitro anti-tumor activity despite repeated tumor challenge against tumor cells expressing all or any one of the three antigens. Superior tumor control was observed as compared to benchmark CAR T cells, without increased cytokine secretion and while sustaining a less effector-differentiated phenotype. In vivo studies showed that CRG-023 CAR T cells were highly active and able to clear Raji lymphoma tumor cells expressing the three target antigens in a dose-response manner and down to the lowest dose tested (1x10CAR cells). Additionally, the data showed that CRG-023 T cells were able to durably clear tumor cells in models mimicking antigen loss in contrast to mono-CAR T cells such as FMC63-containing CD19 CAR T cells.
New Risk • Sep 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$201m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).
Recent Insider Transactions Derivative • Sep 20President notifies of intention to sell stockGina Chapman intends to sell 75k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of September. If the sale is conducted around the recent share price of US$23.33, it would amount to US$1.7m. For the year to December 2022, Gina's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2023, Gina has owned 103.91k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
New Risk • Jul 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.6% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$200m net loss in 3 years).
Buy Or Sell Opportunity • Jun 17Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 42% to US$15.92. The fair value is estimated to be US$20.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
お知らせ • Jun 06CARGO Therapeutics, Inc. Announces the Appointment of Jane Pritchett Henderson as Independent DirectorCARGO Therapeutics, Inc. announced the appointment of Jane Pritchett Henderson to its Board of Directors. Ms. Henderson will also serve as a member of the audit and compensation committees. Ms. Henderson has served as Chief Financial Officer of Apogee Therapeutics since January 2023. Prior to joining Apogee, she served as the Chief Financial Officer and Chief Business Officer of Adagio Therapeutics (now Invivyd, Inc.). She has also served as Chief Financial Officer of Turnstone Biologics, Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, and as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals. Prior to Kolltan Pharmaceuticals, Ms. Henderson served in various financial and business development executive roles at biopharmaceutical companies after spending almost 20 years in healthcare investment banking. She currently serves on the Board of Directors of Akero Therapeutics, Inc. and Ventus Therapeutics and had previously served on the Board of IVERIC (formerly Ophthotech) and Sesen Bio (formerly Eleven Bio).
お知らせ • May 29CARGO Therapeutics, Inc. announced that it expects to receive $110.007 million in fundingCARGO Therapeutics, Inc. announced it has entered into a Securities Purchase Agreement of 6,471,000 shares of the Company’s common stock $0.001 par value per share at issue price $17 for gross proceeds $110,007,000 on May 28, 2024. The closing of the Private Placement is expected to occur on May 30, 2024, subject to the satisfaction of customary closing conditions.
分析記事 • May 10CARGO Therapeutics (NASDAQ:CRGX) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Buy Or Sell Opportunity • May 03Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to US$20.33. The fair value is estimated to be US$25.61, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
お知らせ • Apr 27CARGO Therapeutics, Inc., Annual General Meeting, Jun 04, 2024CARGO Therapeutics, Inc., Annual General Meeting, Jun 04, 2024, at 09:00 Pacific Standard Time. Agenda: To elect two Class I directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected; to consider and ratify the appointment, by the Audit Committee of the company's Board of Directors, of Deloitte & Touche LLP as the independent registered public accounting firm and independent auditor of the company for its year ending December 31, 2024; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
お知らせ • Apr 16CARGO Therapeutics, Inc. Appoints Kapil Dhingra to Board of DirectorsCARGO Therapeutics, Inc. announced it has appointed Kapil Dhingra, M.B.B.S., to the Company’s Board of Directors. Dr. Dhingra is a medical oncologist and a physician-scientist bringing more than 25 years of strategic clinical development experience in oncology, including cell therapy, with a proven track record in drug development, patient care and academic research. Dr. Dhingra’s development experience spans several oncology companies, both as a Board member or in senior leadership. He is currently Chairman of the Board for LAVA Therapeutics, a member of the Board of Supervisors for Servier and a member of the Board of Directors of Black Diamond Therapeutics, Inc., Replimune, Inc., and Median Technologies. He previously served on the Board of Autolus Therapeutics plc from the company’s inception until the recent Biologics License Application (BLA) filing of its CAR T-cell therapy.In 2008, Dr. Dhingra founded and continues to be a managing member of KAPital Consulting, LLC, a healthcare consulting firm providing strategic advisory services to biotechnology companies. Previously he served as Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at The Roche Group (Roche), during which he led numerous drug approvals. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Dr. Dhingra has also served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine and Memorial Sloan Kettering Cancer Center.
Buy Or Sell Opportunity • Apr 02Now 20% undervaluedOver the last 90 days, the stock has risen 4.1% to US$20.91. The fair value is estimated to be US$26.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
Seeking Alpha • Jan 28Cargo Therapeutics: High Venture Interest But Still Early Days For This CAR-T PlayerSummary CARGO Therapeutics is developing cell therapies for cancer patients, with a focus on CD22 targeting CAR-T therapy. The company plans to initiate a Phase 2 program in LBCL - CAR T naïve based on data from ongoing clinical trials. The FDA has issued a safety labeling change for all CAR-T therapies, requiring a warning label due to the risk of T cell malignancies. CRG-022 needs to be differentiated from existing CAR-Ts. Read the full article on Seeking Alpha
Board Change • Dec 31High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. Director Abe Bassan is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Dec 07CARGO Therapeutics, Inc. Announces Formation Scientific Advisory BoardCARGO Therapeutics, Inc. announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy. The SAB will be chaired by Robbie Majzner, MD, co-founder of CARGO and Director of the Pediatric and Young Adult Cancer Cell Therapy Program within the Departments of Pediatric Oncology and Medical Oncology at Dana Farber Cancer Institute and the Division of Hematology/Oncology at Boston Children’s Hospital. Members of the CARGO Scientific Advisory Board are listed below. Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair, and Director of the Pediatric and Young Adult Cancer Cell Therapy Program within the Departments of Pediatric Oncology and Medical Oncology at Dana Farber Cancer Institute and the Division of Hematology/Oncology at Boston Children’s Hospital. Stephen Gottschalk, MD, Chair of the Department of Bone Marrow Transplantation and Cellular Therapy at St Jude Children’s Research Hospital. Andras Attila Heczey, MD, Professor, Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology and Oncology. Marcela Maus, MD, PhD, Associate Professor at Harvard Medical School, the Paula O’Keefe Chair in Oncology, Director of Cellular Immunotherapy at Massachusetts General Hospital (MGH) Cancer Center, Attending Physician in the Hematopoietic Cell Transplant and Cell Therapy Division of Oncology at MGH. Cameron Turtle, MBBS, PhD, Professor and CLEARbridge Chair in Cancer Immunotherapy in the Faculty of Medicine and Health at the University of Sydney; Clinical academic physician at Royal North Shore Hospital, Sydney, Australia.
お知らせ • Nov 11CARGO Therapeutics, Inc. has completed an IPO in the amount of $281.25 million.CARGO Therapeutics, Inc. has completed an IPO in the amount of $281.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,750,000 Price\Range: $15 Transaction Features: Sponsor Backed Offering
